Alcon (ALC) Earnings Date & Reports

Key Takeaways

• Alcon (ALC) is expected to report third-quarter 2026 results on November 10, 2026, after the market close, with a conference call the following morning.
• Wall Street consensus points to core diluted earnings per share (EPS) of roughly $0.88–$0.89 on net sales of about $2.68–$2.75 billion, up from $0.79 on $2.59 billion a year earlier.
• Alcon has beaten consensus EPS estimates in six of its last eight quarters, including a 9% beat in the second quarter of 2026.
• Investors will focus on the Surgical segment's cataract-related demand, the Vision Care segment's dry-eye portfolio, and the ramp of new products such as the Unity equipment platform.
• Full-year 2026 guidance — including 5%–7% constant-currency sales growth and 12%–15% core diluted EPS growth — will be a key barometer for the stock's reaction.

Earnings Context and Why It Matters

Alcon is the world's largest dedicated eye-care company, operating through two segments: Surgical (implantables, consumables, and equipment for cataract, glaucoma, and refractive procedures) and Vision Care (contact lenses and ocular health products). The third-quarter report matters because it arrives after a strong first half in which the company delivered 7% constant-currency sales growth and raised its profitability outlook, even as softness in the cataract procedure market and competitive pressure in implantables persisted. For investors, this print is a read on whether new product momentum — including the Unity platform and the dry-eye franchise led by Tryptyr and Systane — can sustain growth into the year's final quarter and support management's upgraded full-year targets.

Earnings Expectations

Analysts expect Alcon to report core diluted EPS of approximately $0.89 on net sales near $2.68 billion for the three months ended September 30, 2026, according to consensus figures compiled by MarketBeat. That would represent EPS growth of roughly 12.7% and a sales increase of about 3.6% compared with the prior-year quarter, when Alcon posted $0.79 per share on $2.59 billion in net sales. Broader consensus ranges vary modestly, with revenue estimates spanning roughly $2.71 billion to $2.78 billion.

Alcon's most recent quarter set a constructive tone: second-quarter 2026 core diluted EPS of $0.84 topped the $0.77 consensus estimate, while net sales of $2.78 billion edged past expectations. On a reported (IFRS) basis, however, results were distorted by a $402 million non-cash charge tied to the discontinuation of the PowerVision intraocular lens programs, underscoring why investors track core, non-IFRS (International Financial Reporting Standards) measures that exclude such one-time items.

Heading into the report, the company has reiterated full-year guidance of 5%–7% constant-currency (cc) net sales growth, while raising its core operating margin outlook to an increase of 90–190 basis points (bps; one basis point equals one-hundredth of a percentage point) and its core diluted EPS growth target to 12%–15%. Key metrics to watch include Surgical consumables and equipment growth, Implantables performance, and the contact lens and ocular health businesses within Vision Care.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings season, tools like this can help identify stocks approaching catalysts or showing momentum ahead of quarterly reports. Explore the AI Screener to refine your own watchlist.

Market Reaction and Investor Sentiment

Sentiment into Alcon's third-quarter report is cautiously optimistic but not euphoric. The stock has historically responded to earnings surprises, and Alcon's track record of beating consensus — including the second quarter's 9% EPS beat — has supported investor confidence. Still, concerns linger over the softness in the broader cataract procedure market and ongoing competitive pressure in implantables, which management itself flagged in recent quarters. Any signal that procedure volumes are re-accelerating, or that new products such as the Unity platform are scaling faster than expected, would likely be well received. Conversely, a miss on the top line or any downward revision to full-year guidance would test the stock's recent gains.

Forward Outlook and Key Factors to Monitor

Beyond the headline EPS and revenue figures, investors should watch three forward-looking areas. First is the trajectory of the Surgical segment. Cataract procedure volumes have been a persistent soft spot, so management's commentary on demand trends and the pace of the Unity equipment rollout will be central to the growth narrative.

Second is margin execution and tariffs. Alcon has guided to a full-year tariff impact of roughly $40 million to $90 million, partially offset by an expected refund of about $60 million in the third quarter. How these items flow through cost of sales, and whether the raised core operating margin target remains intact, will matter for profitability expectations.

Third is the durability of Vision Care growth, where the dry-eye portfolio — including Tryptyr and Systane — has been a standout. Sustained momentum in ocular health, alongside steady contact lens gains, would reinforce the diversified nature of Alcon's revenue base. Investors will also listen for any updates to full-year guidance and capital-allocation plans, given the company's ongoing share-repurchase program and dividend returns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations